期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

HER-2过表达与乳腺癌内分泌治疗临床疗效的关系 被引量：4

Relationship between HER2 overexpression and the clinical effect of endocrine therapy in breast cancer
下载PDF
导出
摘要 内分泌耐药在乳腺癌治疗中是一个严峻的临床问题 ,其耐药的机制非常复杂且涉及多种基因的参与和调控。研究表明 ,在乳腺癌中HER 2的表达与雌激素受体ER呈负相关 ,但HER 2过表达的乳腺癌患者中仍有将近一半ER为阳性。现综述HER 2过表达。
作者 朱建华 江泽飞 宋三泰
机构地区 军事医学科学院
出处 《国外医学（肿瘤学分册）》 2003年第2期113-115,共3页 Foreign Medical Sciences (Cancer Section)
关键词 乳腺癌 内分泌治疗 耐药 HER-2基因 雌激素受体
分类号 R737.9 [医药卫生—肿瘤] R730.59 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1Witters LM, Kumar R, Chinchilli VM, et al. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody [J].Breast Cancer Res Treat, 1997,42(1):1-5.
  • 2Kunisue H, Kurebayashi J,Otsuki T,et al. Anti-HER-2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogea receptors and HER-2 [J]. Br J Cancer,2000,82(1) :46-51.
  • 3Johnston SR, Head J, Pancholi S, et al. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer [J]. Clin Cancer Res ,2003,9(1 Pt 2) : 524S-532S.
  • 4Kurokawa H, Arteaga CL. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms [J]. Clin Cancer Res,2003 , 9(1 Pt 2):511S-515S.
  • 5Lipton A, Ali SM, Leltzel K, et al. Elecated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. [J]. J Clin Oncol, 2002,20(6) : 1467-1472.
  • 6Ali SM, Leitzel K, Chinchilli VM, et al. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer[J]. Clin Chem, 2002,48(8) : 1314-1320.
  • 7Houston SJ, Plunkett TA, Barnes DM, et al. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer[J]. Br J Cancer, 1999,79(7-8) : 1220-1226.
  • 8Elledge RM, Green S, Ciocca D, et al . HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study [J]. Clin Cancer Res, 1998 ,4(1):7-12.
  • 9Dowsett M, Harper Wynne C, Boeddinghaus I,et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen eceptor-positive primary breast cancer [ J ]. Cancer Res,2001, 61(23) :8452-8458.
  • 10Ellis MJ, Coop A, Singh B, et al . Letrozole is mole effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase Ⅲ randomized trial[J]. J Clin Oncol,2001,19(18) : 3808-3816.

同被引文献32

  • 1姜超,张峰,王少军,邹奇飞.COX-2与HIF-1α在肝癌中的表达与相关性[J].中国普外基础与临床杂志,2006,13(2):142-144. 被引量：6
  • 2郭志强,朱辉,马智勇.HER2/neu癌基因及其产物测定在乳腺癌的临床应用[J].中原医刊,2006,33(11):57-59. 被引量：2
  • 3van de Vijer MJ. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2(HER2) [J].EurJCancer Res,2001,37(1):11- 17.
  • 4Rachel S, Suleiman M,Jiang S, et al. Breast cancer endocrine resistance:how growth factor signaling and estrogen receptor coregulators modulate response[J]. Clin Cancer Research,2003,9:447- 454.
  • 5Jacobs TW, Gown Am, Yaziji H, et al. Specificity of HerceptTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system [J].JClin Oncol, 1999,17(7): 1983 - 1987.
  • 6Lebeau B, Deimling D, Kaltz C, et al. HER-2/Neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization [J].JClin Oncol, 2001,19(12) :354 - 363.
  • 7Piccart M. Closing remarks and treatment guidelines[J]. EurJCancer, 2001,37 (1): 30 - 33.
  • 8Chan KC, Knox WF, GeeJM, et al. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast [J]. Cancer Res, 2002,62 (1): 122 - 128.
  • 9Kunisue H, KurebayashiJ, Otsuki T, et al. Anti-HER-2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER-2[J]. BrJCancer,2000,82(1) :46 - 51.
  • 10Dowsett M, Harper WC, Boeddinghaus I, et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer[J]. Cancer Res, 2001,61 (23):8452 - 8458.

引证文献4

二级引证文献3

国外医学（肿瘤学分册）
2003年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部